Le Cras Lab

Publications

Alharbi, S; Merkle, S; Hammill, AM; Waters, AM; Le Cras, TD. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric Blood and Cancer. 2025; 72:e31605.

McDaniel, CG; Fox, D; Pastura, P; Alharbi, S; Huppert, SS; Cras, TD L. Lyve1-Driven NrasQ61R Causes Edema, Enlarged Lymphatic Vessels, and Hepatic Vascular Defects in Embryonic Mice. Pediatric Blood and Cancer. 2025; 72:e31492.

Pastura, P; McDaniel, CG; Alharbi, S; Fox, D; Coleman, B; Malik, P; Adams, DM; Le Cras, TD. NRASQ61R mutation drives elevated angiopoietin-2 expression in human endothelial cells and a genetic mouse model. Pediatric Blood and Cancer. 2024; 71:e31032.

Engel, ER; Le Cras, TD; Ricci, KW. How we use angiopoietin-2 in the diagnosis and management of vascular anomalies. Pediatric Blood and Cancer. 2024; 71:e30921.

McDaniel, CG; Adams, DM; Steele, KE; Hammill, AM; Merrow, AC; Crane, JL; Smith, CL; Kozakewich, HP W; Le Cras, TD. Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment. Pediatric Blood and Cancer. 2023; 70:e30219.

Boscolo, E; Pastura, P; Schrenk, S; Goines, J; Kang, R; Pillis, D; Malik, P; Le Cras, TD. NRASQ61R mutation in human endothelial cells causes vascular malformations. Angiogenesis. 2022; 25:331-342.

Henry, BM; de Oliveira, MH S; Cheruiyot, I; Benoit, JL; Cooper, DS; Lippi, G; Le Cras, TD; Benoit, SW. Circulating level of Angiopoietin-2 is associated with acute kidney injury in coronavirus disease 2019 (COVID-19). Angiogenesis. 2021; 24:403-406.